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Abstract
Obesity and type-2 diabetes (T2D) have increased dramatically over the past several decades, in
parallel. One of the major links between these two disorders is chronic, low-grade inflammation 1.
Prolonged nutrient excess promotes the accumulation and activation of leukocytes in visceral
adipose tissue (VAT) and ultimately other tissues, which provokes metabolic abnormalities such
as insulin resistance, T2D and fatty-liver disease. While invasion of VAT by pro-inflammatory
macrophages is considered to be a key event driving adipose-tissue inflammation and insulin
resistance, little is known about the roles of other immune-system cell-types in these processes.
Recently, a unique population of VAT-resident regulatory T cells (Tregs) was implicated in control
of the inflammatory state of adipose tissue and, thereby, insulin sensitivity 2. We have identified
peroxisome proliferator-activated receptor gamma (PPARγ), the “master-regulator” of adipocyte
differentiation, as a critical molecular orchestrator of VAT Treg accumulation, phenotype and
function. Unexpectedly, PPARγ expression by VAT Tregs was necessary for complete restoration
of insulin sensitivity in obese mice by the thiazolidinedione (TZD) drug, pioglitazone (Pio). These
findings suggest a previously unknown cellular mechanism for this important class of T2D drugs,
and provide proof-of-principle that discrete populations of Tregs with unique functions can be
precisely targeted to therapeutic ends.
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A unique population of Foxp3+CD4+ Tregs was recently found in the VAT of normal
individuals 2, as a much higher fraction of the CD4+ T cell compartment than that usually
observed in lymphoid or other non-lymphoid tissues. VAT Tregs had a phenotype readily
distinguishable from that of their counterparts in the spleen and lymph nodes (LNs),
including a distinct gene-expression profile, T cell receptor repertoire, and pattern of
chemokine and chemokine receptor expression. Adipose-tissue inflammation and both local
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tand systemic metabolic indices were improved or worsened by global enrichment or
impoverishment, respectively, of Tregs 2–4. However, a lack of appropriate reagents has so
far precluded an assessment of the precise role of fat-resident Tregs.
The molecules that orchestrate the distinctive properties of VAT Tregs are unknown.
Comparing the gene-expression profiles of visceral-fat and lymphoid-organ Tregs, we were
struck by the elevated level of transcripts encoding the nuclear receptor PPARγ in the
former (Fig. 1a, Suppl. Fig. S1a). The specificity of this increase was highlighted by a
comparison of Pparg transcript levels across a large library of microarray data-sets (more
than 350) encompassing T cells of diverse subsets, activation statuses and localizations (Fig.
1b). Because of the crucial role of PPARγ in adipocyte differentiation, as well as its anti-
inflammatory activities 5, we hypothesized that its expression in VAT Tregs might be
responsible for at least some of their unique features.
To identify genes whose expression was correlated, either positively or negatively, with that
of Pparg, we performed a clustering analysis across transcript profiles obtained from VAT
and LN Tregs of mice differing in their metabolic state: either lean [C57Bl/6 (B6) animals of
various ages kept on normal chow (NC)] or obese [B6.Lepob/ob (ob/ob) animals of varying
age on NC or B6 animals on a high-fat diet (HFD)] (Suppl. Fig. S1b and c). The set of loci
whose expression was co- or anti-correlated with Pparg transcript levels encompassed the
majority of those most strongly up- (red) or down- (blue) regulated, respectively, in visceral-
fat versus lymphoid-tissue Tregs 2 (Fig. 1c). The co-clustered transcripts included many that
encode chemokines or chemokine receptors involved in leukocyte migration and
extravasation (e.g., Ccr2 and 3, Cxcr6, Cxcl2 and 3), several encoding molecules involved in
lipid metabolism (e.g., Pcyt1a, Dgat1), and Il10 transcripts.
We directly evaluated the role of PPARγ in specifying the VAT Treg phenotype by
retrovirally transducing Foxp3 alone or together with Pparg into naïve CD4+ T cells
activated in vitro with anti-CD3/CD28-coated beads (neither transcription factor being
expressed at detectable levels in the host CD4+ T cells). Two isoforms of PPARγ have been
described, referred to as PPARγ1 and PPARγ2 5; while adipocytes are known to express
both of them, the isoform(s) made by T lymphocytes are not well characterized. Feature-
level analysis of Pparg transcripts, exploiting our existing Affymetrix ST 1.0 microarray
data, revealed that mRNAs corresponding to both PPARγ1 and PPARγ2 were expressed by
VAT Tregs, with predominance of the former (Suppl. Fig. S2a), while the low-level
transcripts made by the other T cell populations encoded primarily PPARγ2 (not shown).
Therefore, we evaluated each isoform’s ability to cooperate with Foxp3 to promote the VAT
Treg gene-expression signature. Most transcripts are distributed in a gray cloud along the
diagonal in the Fold-change/Fold-change (FC/FC) plot of Fig. 2a, showing that Pparg1 and
Pparg2 induced the expression of a similar set of genes when co-transduced with Foxp3; the
slight tilt towards the x-axis indicates that Pparg1 transduction was a bit more potent. Each
isoform promoted expression of the above-discussed Pparg co-cluster (red cloud along the
diagonal), while only Pparg1 repressed expression of the bulk of the Pparg anti-cluster (blue
cloud along the x-axis). Similarly, as illustrated most clearly by the Pparg+Foxp3 vs Foxp3-
alone “volcano plots” (Fig. 2b and c), each PPARγ isoform could collaborate with Foxp3 to
up-regulate a substantial fraction of the genes characteristic of the VAT Treg up-signature
(pink, skewed to the right in panels b and c). However, the corresponding down-signature
was partially recapitulated only after Pparg1+Foxp3 transduction (green, skewed to the left
in panel c but not panel d).
Since adequate PPARγ ligand might not be available in this in vitro context, we explored
the effect of adding a synthetic agonist, the TZD drug, Pio. Twenty-four hours after
retroviral infection, double (Pparg1+Foxp3 or Pparg2+Foxp3) or single (Foxp3-alone)
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ttransductants were treated with Pio for forty-eight hours. The most striking effect of this
agonist, whether in the context of Pparg1 or Pparg2, was the augmentation of a set of “lipid
metabolism” genes, some of which were reported to be differentially expressed in VAT vis-
á-vis LN Tregs in a previous ex vivo microarray analysis 2. This influence was most obvious
on FC/FC plots (Fig. 2d and e), which serve to isolate the effect of Pio in the context of each
isoform (as aligned towards the x-axis). Up-regulated genes involved in lipid metabolism
included those coding for: fatty-acid transporters (Cd36, Slc27a2), enzymes involved in
fatty-acid synthesis (Lipe and Scd1), an enzyme essential for fatty-acid oxidation (Cpt1a),
an enzyme responsible for the synthesis of triglycerides (Dgat1), and a lipid-droplet-
associated protein (Plin2). Similar results were obtained with Rosiglitazone (Rosi), another
TZD drug, or with GW1929, a potent non-TZD PPARγ agonist (Suppl. Figs. S2b and c;
note change in axis labels vis-á-vis Figs. 2d and e). The fact that PPARγ could cooperate
with Foxp3 to impose a VAT Treg phenotype on naïve CD4+ T cells raised the question of
whether the two transcription factors interact in some way. Indeed, both PPARγ isoforms
were co-immunoprecipitated with Foxp3 in transduced HEK293 cells, arguing that they
have the potential to interact, either directly or within a shared complex (Fig. 2f).
(Unfortunately, we could not obtain adequate material from ex vivo T cells to perform an
analogous experiment.)
To assess the importance of PPARγ for the VAT Treg phenotype in vivo we abrogated its
expression specifically in Tregs by crossing a mouse line carrying “floxed” Pparg with a line
expressing the Cre recombinase under the dictates of Foxp3 promoter/enhancer elements.
The Treg specificity of Cre expression in such mice has been validated in a number of
contexts. At 25 weeks, the resulting mutants (Treg-Pparg mut) had lower fractions and
numbers of VAT Tregs than their Pparg wild-type (Pparg wt) littermates (carrying the
Foxp3-Cre transgene); in contrast, the representation of Tregs in the lymphoid organs of
mutants was normal (Fig. 3a). While VAT Tregs in wt mice increased >2.5-fold between 15
and 25 weeks to eventually constitute >40% of the CD4+ T cell compartment, this subset
remained below ~10% in mutant mice (Suppl. Fig. S3a). The Tregs remaining in the VAT
(but not those in the spleen) of mutants had a lower mean fluorescence-intensity (MFI) of
Foxp3 expression than that of their wt counterparts (Suppl. Fig. S3b). A volcano plot
comparing gene expression in VAT Tregs from Pparg wt and Treg-Pparg mut mice revealed
the VAT Treg up-signature (pink, skewed to the right) to be under-represented in mutant T
cells while, conversely, the down-signature (green, skewed to the left) was over-represented
(Fig. 3b). VAT and lymphoid-organ Tregs were much more similar in Treg-Pparg mut than in
Pparg wt mice (Suppl. Fig. S3c); this difference reflected alterations at the level of VAT
Tregs as the absence of PPARγ expression in LN Tregs had little impact (Suppl. Fig. 3d).
This observation was confirmed at the protein level (Suppl. Fig. S4): down-regulation of
CCR2, Gata-3, KLRG1 and CD69 in mutant vis-á-vis wt VAT Tregs to resemble the lower
levels in lymphoid-tissue Tregs; up-regulation of CD103 and CD86 in mutant VAT Tregs to
approach the higher levels in lymphoid Tregs. Thus, PPARγ is an important factor
controlling the accumulation and phenotype of Tregs residing in adipose tissue.
How did the loss of PPARγ influence the turnover of Tregs residing in VAT? Addressing
this question was more complex than simply comparing the half-life of VAT Tregs in wild-
type and mutant mice because the residual Tregs in the latter animals are likely to be atypical
“survivors” and/or recruits from the lymphoid Treg pool exploiting a niche empty of the
usual competitors. So we performed an acute assay, monitoring Treg populations in wt mice
over a few days of treatment with the irreversible PPARγ inhibitor, GW9662 (Suppl. Fig.
S5a). There were no significant differences in either VAT or spleen Treg fraction or numbers
in the drug- vs vehicle-treated animals (Suppl. Fig. S5b and c). However, there was a
progressive decline in the fraction of Gata-3+ Tregs in VAT (but not in spleen) and a parallel
decrease in the Gata-3 MFI (Suppl. Fig. S5d and e). Gata-3 is a transcription factor highly
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tover-represented in VAT versus lymphoid-tissue Tregs, and is down-regulated in the absence
of PPARγ (Suppl. Fig. S4). Altogether, our data indicate that PPARγ may control both the
establishment and maintenance of the VAT Treg phenotype.
Secondarily, the Treg-Pparg mut mice had fractional and numerical increases in some, but
not all, adipose-tissue monocyte/macrophage subsets: pro-inflammatory
CD11b+CD11c+F4/80+ macrophages (Suppl. Fig. S6a and S6c) and pro-inflammatory
CD11b+Ly6chi monocytes (Suppl. Fig. S6b, left and S6d, left), but not CD11b+Ly6clow
monocytes (Suppl. Fig. S6b, right and S6d, right), considered to be anti-inflammatory. There
were no changes in fractions or numbers of CD8+ T or B cells in VAT of mutant mice
(Suppl. Fig. S6e–h).
Pio is a well-known insulin-sensitizing agent that improves metabolic indices in obese mice
and humans. Given its ability to enhance the unique fat Treg signature in cultured cells (Fig
2d and e), we wondered how this drug might impact VAT Tregs in obese (HFD-fed) mice.
There was an impressive enrichment of the fraction and number of Tregs in epididymal
adipose tissue of animals treated with Pio (Figs. 4a and Suppl. Fig. S7a), which was a
specific effect, not seen in the spleen, subcutaneous fat, peri-renal fat or liver (Figs. 4a and
Suppl. Fig. S7b). There were also marked phenotypic changes in the epididymal fat Treg
population of Pio-treated vis-á-vis untreated obese mice: an overall shift of the gene-
expression profile towards that typical of VAT Tregs (Fig. 4b); an increase in the Foxp3 MFI
(Suppl. Fig. S7c); a PPARγ-dependent enrichment of cells expressing Gata-3 (Suppl. Fig.
S7d); and enhanced cell-surface display of the lipid scavenger, CD36 (Fig. 4c). As PPARγ
ligands are known to stimulate oxidized low-density lipoprotein (oxLDL) uptake by
augmenting levels of CD36 on the surface of macrophages 6, we stained Tregs with Nile red,
a dye that selectively binds to intracellular lipid droplets. VAT, but not spleen, Tregs readily
took up lipids, especially in response to Pio (Fig. 4d). This process was PPARγ-dependent
as the Pio-induced increase in CD36 expression and Nile red staining were both greatly
dampened in Treg-Pparg mutant mice (Suppl. Fig. S7e and f). Thus, Pio accentuates the
accumulation and phenotype of fat Tregs in epididymal fat depots of obese mice.
The striking increase in the representation of and alterations in the phenotype of VAT Tregs
provoked by Pio treatment of obese mice raised the question of whether this population
contributes to the insulin-sensitizing effect of Pio. In analogy to the human context, we
compared immunologic and metabolic parameters in obese (HFD-fed) Pparg wt and Treg-
Pparg mut mice as a function of Pio co-treatment. As anticipated, the VAT Treg population
of wt animals fed a HFD was quite low, and it increased substantially when Pio was
included in the diet (Fig 4e). Also as expected, the representation of VAT Tregs in mutant
animals on HFD was similar to that of their wt counterparts: HFD in and of itself results in
death and/or evacuation of typical VAT Tregs, so abrogation of PPARγ expression in this
context has no further impact. Pio could not expand VAT Tregs in the mutant (Fig 4e). Pio
had differential effects on conventional adipose-tissue monocyte/macrophage populations in
HFD-fed mutant mice: pro-inflammatory macrophages (CD11b+CD11c+F4/80+) were
diminished, though not to the degree seen in wt littermates (Suppl. Fig. S8a); in contrast,
pro-inflammatory monocytes (CD11b+Ly6chi) did not undergo their usual reduction (Suppl.
Fig. S8b, left); while anti-inflammatory monocytes (CD11b+Ly6clow) uncharacteristically
declined (Fig. S8b, right). Pio treatment of obese mutant mice was less effective than
treatment of their wt counterparts at normalizing systemic metabolic parameters:
homeostatic model assessment of insulin resistance (HOMA-IR) (Fig. 4f), glucose and
insulin tolerance (Fig. 4g and Suppl. Fig. S8c), and phosphorylated (p)AKT levels in
multiple organs (Suppl. Fig. S8d). At least some of the muted metabolic response to Pio
reflected events in VAT, evidenced by the lack of normalization of pAKT values at that site.
The Pio treatment clearly worked, however, as we did see in both wt and mutant drug-
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ttreated HFD-fed mice the expected increase in epididymal fat-pad weight (Suppl. Fig. S9a),
though not in total body weight (not shown); a coupled decrease in adipocyte numbers and
increase in adipocyte size (Suppl. Fig. S9b and c); and increased levels of serum adiponectin
and Adipoq transcripts (Suppl. Fig. S9d). Leptin (Lep) transcript levels were unchanged in
both wt and HFD-fed individuals (Suppl. Fig. S9e), as anticipated 7.
The main conclusion from our results is that PPARγ is a major orchestrator of the unique
properties of VAT Tregs. This nuclear receptor collaborates with Foxp3 to impose on naïve
CD4+ T cells the transcriptional signature characteristic of VAT Tregs. Interestingly, both
PPARγ isoforms can promote the fat Treg up-signature in conjunction with Foxp3, but only
isoform 1 drives the down-signature. This constitutes a rare dysjunction in the activities of
the two PPARγ isoforms, which differ only an additional 30 amino acids at the N-terminus
of PPARγ2. Experimental manipulation of PPARγ specifically in Foxp3+ cells had a clear
and precise impact on the accumulation and phenotype of Tregs in epididymal fat depots. A
newly discovered property was that VAT, but not lymphoid-tissue, Tregs can take up lipids,
an intriguing adaptation to the tissular environment, not shared by conventional T cells
residing at the same site. It remains to be determined whether this feature promotes Treg
survival or effector functions, or whether it is an epiphenomenon.
Our data also indicate that PPARγ expressed by Tregs contributes substantially to the
insulin-sensitizing activity of Pio. It was initially assumed, given this transcription factor’s
role in fat-cell differentiation, that TZD drugs improve metabolic parameters in obese
individuals by activating PPARγ in adipocytes. While this notion has received experimental
support 8, other studies have argued for the importance of PPARγ expression in
macrophages 9, 10, muscle 11 and the central nervous system 12, 13. On first consideration, it
seems difficult to explain the need for PPARγ across such a broad range of cell-types, but
several points should be kept in mind. First, TZD drugs may impact several processes
upstream of insulin resistance, e.g. ingestive behavior, adipocity and inflammation; PPARγ-
driven programs in different cell-types may influence these processes differentially.
Secondly, abrogating PPARγ expression in different cell-types appears to have organ-
specific effects on insulin resistance 11–13. And third, there is increasing appreciation that
the gene promoters used to generate transgenic mouse lines with cell-type-specific ablation
of PPARγ can be “leaky.” Delineating the cell-type(s) critical for Pio’s protective effect on
metabolic disorders is imperative given current concerns over the side-effects of the TZD
class of compounds and the resultant search for alternative drugs 14.
Lastly, our results provide proof-of-principle that it is possible to target a designated
population of Tregs for a particular therapeutic goal. The emerging notion that the
Foxp3+CD4+ Treg compartment includes a number of sub-types with distinct phenotypes,
localizations and effector functions 15 has evoked the exciting possibility of developing
strategies to precisely expand or contract disease-relevant Tregs, leaving the bulk of the
compartment intact to maintain immune homeostasis.
METHODS SUMMARY
Source and maintenance of mice are described in Methods. Experimentals and controls were
always littermate-matched males (eg, Ppargfl/fl -FoxP3YFP-Cre and Ppargwt -FoxP3YFP-Cre).
HFD and NC animals were fed a diet containing 60 kcal% and 10 kcal% fat, respectively.
Mice on HFD+Pio were fed the above-described diet mixed with Pio at a concentration of
100 mg per kg of food. Metabolic studies were performed on mice fed HFD +/− Pio for 12
weeks. For GTTs, glucose (2.0g per kg body-weight) was administered by ip injection after
an overnight fast. For ITTs, insulin (0.75 units) was administered by ip injection after 4
hours of fasting.
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tCD4+CD25− T cells were activated for 48-hours with anti-CD3/CD28 antibody-coated
beads plus recombinant human IL-2 before retroviral transduction and cultured for 72 hours
after transduction. In selected experiments, 24 hours after infection, transduced cells were
treated with 1μM Pio, Rosi or GW1929, or with vehicle (DMSO) for 48 hours before
sorting.
For T cell analysis, cells were stained with anti-CD45, -CD3, -CD4, -CD8, -CD25-and
sometimes anti-CD36, fixed, permeabilized and intracellularly stained for Foxp3 and
Gata-3. For intracellular lipids, cells were stained with anti-CD3, -CD4 and Nile red (1μg/
mL). RNA from double-sorted cells was prepared for microarray analysis 2, and hybridized
to GeneChip Mouse Genome M1.0 ST arrays (Affymetrix).
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tFig. 1. Transcripts directly or inversely correlated with Pparg expression in VAT Tregs
(a) Microarray analysis. Normalized expression values for transcripts isolated from Tregs
from epididymal fat versus LN of 30-week-old retired-breeder B6 males (in triplicate). (b)
Expression of Pparg in a library of microarray datasets from diverse T cell populations:
different subsets, activation statuses, or location. (c) A volcano plot comparing gene
expression in VAT and LN Tregs of NC-fed B6 mice. The Pparg co- and anti-cluster
transcripts defined in Suppl. Fig. 1b are superimposed in red and blue, respectively. Some of
the characteristic of VAT Treg genes are indicated. P values from a chi-square test.
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tFig. 2. Cooperation between PPARγ and Foxp3
Naive CD4+CD25− T cells were stimulated ex vivo and transduced with retroviruses
encoding Foxp3 (MSCV IRES-GFP) plus Pparg1 or Pparg2 (both MSCV IRES-Thy1.1).
Cells were sorted for green-fluorescent protein (GFP) and/or Thy1.1 positivity before RNA
processing. (a) An FC/FC plot comparing gene-expression values for double-transductants
expressing Pparg1 and Foxp3 versus single-transductants expressing Foxp3 only (x-axis)
vis-á-vis double-transductants expressing Pparg2 and Foxp3 versus single-transductants
expressing Foxp3 (y-axis). Pparg co-cluster and anti-cluster genes are superimposed in red
and blue, respectively. (b, c) Genes from the VAT Treg up- and down-signature highlighted
in pink and green, respectively, on a volcano plot comparing P value versus FC for probes
from double-transductants expressing Foxp3 and Pparg1 or Foxp3 and Pparg2 versus single-
transductants expressing Foxp3 alone. The VAT Treg up- and down-signatures were defined
as described in Methods. P values from a chi-square test. (d, e) 24 hours after transduction
of naïve CD4+ T cells, double-transductant (Pparg1+Foxp3 or Pparg2+Foxp3) or single-
transductant (Foxp3 alone) cultures were treated with Pio (1μM) for 48 hours. FC/FC plots
comparing gene expression values of Pio-treated versus vehicle-treated double-transductants
expressing Pparg1 or Pparg2 plus Foxp3 (x axis) vis-á-vis Pio-treated versus vehicle-treated
single-transductants expressing Foxp3 alone (y axis). Some genes involved in lipid
metabolism are indicated. Mean expression values calculated from three independent
experiments. (f) Association of Foxp3 with PPARγ determined by co-immunoprecipitation.
Anti-PPARγ1+2 antibody was used to immunoprecipitate PPARγ1 or PPARγ2 from
nuclear lysates of HEK293 cells co-transduced with Foxp3 and Pparg1 or Pparg2.
Immunoblots were probed with anti-Foxp3.
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tFig. 3. In vivo effects of abrogating PPARγ expression specifically in Tregs
(a) Treg representation. Cells were isolated from the spleen or stromovascular fraction (SVF)
of epididymal fat (epi-fat) of 25-week-old mice lacking PPARγ specifically in Tregs (Treg-
pparg mut) or littermate controls (Pparg wt). Tregs are defined as CD45+CD3+CD4+Foxp3+.
Left, representative dot plots (of at least 3 experiments); center, summary data (for fraction
of CD4+ cells); right, numbers per gram of tissue. Dot plot numbers indicate the percentage
of cells in that gate for that particular experiment. P values according to the Student’s T test:
*P<0.05, **P<0.01, ***P< 0.001; NS=not significant. Error bars represent the mean ± SD.
(b) Expression of VAT Treg signature genes in Treg-Pparg mut mice. A volcano plot
comparing P value versus FC for probes from wt versus mutant VAT Tregs. Genes from the
VAT Treg up- and down-signature are highlighted in pink and green, respectively. P
determined by the chi-square test.
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tFig. 4. Pio promotion of epididymal fat Treg numbers and phenotype
At 9 weeks of age, Pparg wt and Treg-Pparg mut mice were fed HFD +/− Pio for 13 weeks.
Cells from the spleen and epididymal fat SVF were stained and analyzed by flow cytometry.
Numbers on dot plots indicate the percentage of cells in that gate for that particular
experiment (representative of ≥3 experiments). (a) Tregs from Pparg wt mice on HFD +/−
Pio. Left, representative dot plots; right, summary data. (b) Expression of VAT Treg
signature genes in Pparg wt mice on HFD+/−Pio. A volcano plot comparing P value versus
FC for probes from VAT Tregs isolated from Pparg wt mice on HFD+Pio versus HFD alone.
Genes from the VAT Treg up- and down-signature are highlighted in pink and green,
respectively. P determined by the chi-square test. (c) MFI of CD36 expression by Tregs.
ΔMFI indicates, for gated CD3+CD4+Foxp3+ cells, the difference in CD36 expression for
HFD-fed mice +/− Pio treatment. Epi-fat ΔMFI = 3828±1362 (*P=0.039); spleen ΔMFI =
−182±597 (NS). (d) Cells were isolated from the spleen or epi-fat SVF of B6.Foxp3-(YFP
−)Cre mice kept on HFD+/−Pio for 13 weeks, and stained for CD3, CD4 and Nile red.
*P=0.01. (e) Treg fraction. Cells from spleen or epi-fat SVF were stained and analyzed by
flow cytometry. (f) Insulin sensitivity. Mice were assessed for blood fasting-glucose and
fasting-insulin levels. These values were used to calculate the HOMA-IR. (g) Glucose
tolerance. Left: intraperitoneal GTT on wt mice. Center: GTT on mutant mice. Right: area
under the curve (AUC) calculations. n=13–14 mice per group. P values calculated using the
Student’s T test. Unless otherwise specified: *P<0.05, **P<0.01, ***P< 0.001; NS=not
significant. Error bars represent the mean ± SD for immunological parameters, mean ± SE
for metabolic parameters, as is standard practice in the respective fields.
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